Furthermore, we demonstrated that CLL cell lines harboring del(11q) and TP53 mutations show only partial responses to B cell receptor signaling inhibitors, but may potentially benefit from ATR inhibition. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.